Abstract: Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl-?-cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.

Abstract: Provided is a pharmaceutical composition for the treatment of disorders such as Niemann-Pick disease and GM1 gangliosidosis which are caused by the storage of cholesterol, such as lysosomal storage disease. Also provided is a method for screening for said pharmaceutical compositions that uses iPS cell strains that phenocopy phentotypes of these disorders. Provided is a pharmaceutical composition for the treatment and/or prevention of lysosomal storage disease, characterized by containing hydroxypropyl-?-cyclodextrin as an active ingredient. Also provided are an iPS cell strain derived from patients suffering from intractable disorders and prepared using a new temperature-sensitive Sendai virus vector, and a screening method for pharmaceuticals using said iPS cell strain.

Abstract: Provided is a method of determining the amount of cholesterol in high-density lipoprotein (HDL), which comprises reacting an HDL-containing sample with cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase in the presence of a reagent for aggregating lipoproteins- except HDL, and determining the amount of hydrogen peroxide or reductive co-enzyme formed therein.

Abstract: Cholesterol in low-density lipoprotein (LDL) or very low-density lipoprotein (VLVL) in a sample is determined in the presence of a sugar compound and/or a protein-solubilizing agent.

Abstract: The present invention provides a preparation for percutaneous absorption comprising as an effective component a prostaglandin I.sub.2 derivative and a fatty acid or a derivative thereof, or a mixture of two or more of these, which has high percutaneous permeability of the PGI.sub.2 derivative. Particularly, the present invention provides a preparation for percutaneous absorption comprising 5,6,7-trinor-4,8-inter-m-phenylene PGI.sub.2 derivative and a C.sub.6 -C.sub.24 fatty acid, a salt thereof or an ester thereof, or a mixture of two or more of these, which has high percutaneous permeability of the PGI.sub.2 derivative. This preparation for percutaneous absorption suggests a possibility to last pharmacological effects and to reduce side effects. Thus, the preparation is expected to be used for therapy of various diseases, aiming at topical and systemic actions.

Abstract: Provided are a method of determining the amount of cholesterol in high-density lipoprotein (HDL), which comprises measuring the amount of cholesterol in low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) and chylomicron (CM) in a sample in the presence of a sugar compound and/or a protein solubilizing agent, and calculating the difference between the amount of cholesterol in LDL, VLDL and CM and the total amount of cholesterol in the sample, and a method of determining the amount of cholesterol in HDL, which comprises measuring the amount of cholesterol in HDL in a sample in the presence of a sugar compound and/or a protein solubilizing agent.

Abstract: Provided is a method of determining the amount of cholesterol in high-density lipoprotein (HDL), which comprises reacting an HDL-containing sample with cholesterol esterase and cholesterol oxidase or cholesterol dehydrogenase in the presence of a reagent for aggregating lipoproteins except HDL, and determining the amount of hydrogen peroxide or reductive co-enzyme formed therein.

Abstract: The dissolution of lipophilic compounds in aqueous solutions of hydroxypropylcyclodextrins can be accelerated by the addition of co-solubilizers, such as ethanol or ammonia, which again can be removed, together with water, by evaporation or by freeze-drying leaving lipophile: hydroxypropylcyclodextrin complexes as a residue. The co-solubilizer method was used successfully with steroid drugs (5-androstene-3.beta.,17.beta.-diol, 4-androstene-3,17-dione, dehydroepiandrosterone, dexamethasone, 5-.alpha.-dihydro-testosterone, 6-methylprednisolone, and testosterone), peptides (gramicidin S) and a macrocyclic antibiotic (amphotericin B). The complexes prepared in this manner were amorphous and possessed satisfactory stability.